185 related articles for article (PubMed ID: 17497355)
41. Preparation and the influencing factors of cetirizine hydrochloride microemulsion.
Sun Y; Jiang Y; An K
Artif Cells Blood Substit Immobil Biotechnol; 2011 Jun; 39(3):174-6. PubMed ID: 20946090
[TBL] [Abstract][Full Text] [Related]
42. Multifunctional nanoparticles from albumin for stimuli-responsive efficient dual drug delivery.
Nosrati H; Abhari F; Charmi J; Davaran S; Danafar H
Bioorg Chem; 2019 Jul; 88():102959. PubMed ID: 31075743
[TBL] [Abstract][Full Text] [Related]
43. Glucose cryoprotectant affects glutathione-responsive antitumor drug release from polysaccharide nanoparticles.
Curcio M; Blanco-Fernández B; Costoya A; Concheiro A; Puoci F; Alvarez-Lorenzo C
Eur J Pharm Biopharm; 2015 Jun; 93():281-92. PubMed ID: 25917641
[TBL] [Abstract][Full Text] [Related]
44. Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates.
Myc A; Douce TB; Ahuja N; Kotlyar A; Kukowska-Latallo J; Thomas TP; Baker JR
Anticancer Drugs; 2008 Feb; 19(2):143-9. PubMed ID: 18176110
[TBL] [Abstract][Full Text] [Related]
45. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.
Cuiné JF; Charman WN; Pouton CW; Edwards GA; Porter CJ
Pharm Res; 2007 Apr; 24(4):748-57. PubMed ID: 17372700
[TBL] [Abstract][Full Text] [Related]
46. Lipid and TPGS based novel core-shell type nanocapsular sustained release system of methotrexate for intravenous application.
Katiyar SS; Kushwah V; Dora CP; Jain S
Colloids Surf B Biointerfaces; 2019 Feb; 174():501-510. PubMed ID: 30497012
[TBL] [Abstract][Full Text] [Related]
47. Heterogeneous response of different tumor cell lines to methotrexate-coupled nanoparticles in presence of hyperthermia.
Stapf M; Pömpner N; Teichgräber U; Hilger I
Int J Nanomedicine; 2016; 11():485-500. PubMed ID: 26893557
[TBL] [Abstract][Full Text] [Related]
48. [Water in oil microemulsions containing NaCl for transdermal delivery of fluorouracil].
Xiao YY; Liu F; Chen ZP; Ping QN
Yao Xue Xue Bao; 2011 Jun; 46(6):720-6. PubMed ID: 21882535
[TBL] [Abstract][Full Text] [Related]
49. Methotrexate-grafted-oligochitosan micelles as drug carriers: synthesis and biological evaluations.
Fattahi A; Asgarshamsi M; Hasanzadeh F; Varshosaz J; Rostami M; Mirian M; Sadeghi-aliabadi H
J Mater Sci Mater Med; 2015 Feb; 26(2):119. PubMed ID: 25677115
[TBL] [Abstract][Full Text] [Related]
50. Anionic clay as the drug delivery vehicle: tumor targeting function of layered double hydroxide-methotrexate nanohybrid in C33A orthotopic cervical cancer model.
Choi G; Piao H; Alothman ZA; Vinu A; Yun CO; Choy JH
Int J Nanomedicine; 2016; 11():337-48. PubMed ID: 26855572
[TBL] [Abstract][Full Text] [Related]
51. Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics.
Garg NK; Singh B; Jain A; Nirbhavane P; Sharma R; Tyagi RK; Kushwah V; Jain S; Katare OP
Colloids Surf B Biointerfaces; 2016 Oct; 146():114-26. PubMed ID: 27268228
[TBL] [Abstract][Full Text] [Related]
52. Methotrexate anticancer drug delivery to breast cancer cell lines by iron oxide magnetic based nanocarrier.
Attari E; Nosrati H; Danafar H; Kheiri Manjili H
J Biomed Mater Res A; 2019 Nov; 107(11):2492-2500. PubMed ID: 31298774
[TBL] [Abstract][Full Text] [Related]
53. In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles.
Nogueira DR; Tavano L; Mitjans M; Pérez L; Infante MR; Vinardell MP
Biomaterials; 2013 Apr; 34(11):2758-72. PubMed ID: 23352041
[TBL] [Abstract][Full Text] [Related]
54. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study.
Abdelbary AA; AbouGhaly MH
Int J Pharm; 2015 May; 485(1-2):235-43. PubMed ID: 25773359
[TBL] [Abstract][Full Text] [Related]
55. Ionic liquid based microemulsion with pharmaceutically accepted components: Formulation and potential applications.
Moniruzzaman M; Kamiya N; Goto M
J Colloid Interface Sci; 2010 Dec; 352(1):136-42. PubMed ID: 20825949
[TBL] [Abstract][Full Text] [Related]
56. Induction of Au-methotrexate conjugates by sugar molecules: production, assembly mechanism, and bioassay studies.
Wang WY; Zhao XF; Ju XH; Liu P; Li J; Tang YW; Li SP; Li XD; Song FG
Int J Pharm; 2018 Mar; 538(1-2):65-78. PubMed ID: 29341908
[TBL] [Abstract][Full Text] [Related]
57. Design of fenofibrate microemulsion for improved bioavailability.
Hu L; Wu H; Niu F; Yan C; Yang X; Jia Y
Int J Pharm; 2011 Nov; 420(2):251-5. PubMed ID: 21907776
[TBL] [Abstract][Full Text] [Related]
58. 5-Fluorouracil simultaneously maintains methotrexate antineoplastic activity in human breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M
Anticancer Res; 1999; 19(2A):985-8. PubMed ID: 10368642
[TBL] [Abstract][Full Text] [Related]
59. Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan.
Rajpoot P; Bali V; Pathak K
Int J Pharm; 2012 Apr; 426(1-2):219-230. PubMed ID: 22301424
[TBL] [Abstract][Full Text] [Related]
60. Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study.
Shah N; Seth A; Balaraman R; Sailor G; Javia A; Gohil D
Drug Dev Ind Pharm; 2018 Apr; 44(4):687-696. PubMed ID: 29168671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
